BiotechTube

DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Persistent Corneal Epithelial Defect

Conditions

Persistent Corneal Epithelial Defect

Trial Timeline

Sep 1, 2009 → —

NCT ID
NCT00988494

About DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution

DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution is a phase 2 stage product being developed by Santen Pharmaceutical for Persistent Corneal Epithelial Defect. The current trial status is completed. This product is registered under clinical trial identifier NCT00988494. Target conditions include Persistent Corneal Epithelial Defect.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00988494Phase 2Completed

Competing Products

20 competing products in Persistent Corneal Epithelial Defect

See all competitors
ProductCompanyStageHype Score
E7777 9 mcg/kgEisaiPhase 3
77
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment EAstraZenecaPhase 1
33
AZD0837 + VKA INR 2-3AstraZenecaPhase 2
52
AZD0837 + AspirinAstraZenecaPhase 2
52
Montelukast to placebo + Placebo to montelukastMerckPre-clinical
23
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone AcetateNovartisPhase 2
52
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
85
CertoparinNovartisPhase 3
77
Omalizumab + PlaceboNovartisPhase 3
77
RivastigmineNovartisApproved
85
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 daysNovartisPhase 2
52
Indacaterol + Placebo to IndacaterolNovartisPhase 2
52
Omalizumab + PlaceboNovartisApproved
85
placebo + iv sildenafilPfizerPhase 3
76
etanercept + placeboPfizerPhase 2
51
SildenafilPfizerPhase 2
51
irbesartan + placeboSanofiApproved
84
iloprostBayerPre-clinical
20
IV Remodulin + PlaceboUnited TherapeuticsPhase 2
49
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)GlaukosPhase 2
49

Other Products from Santen Pharmaceutical

Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77